Other NLRP3 inhibitors, such as MCC950, β-hydroxybutyrate, Bay 11-7082, and Ac-YVAD-CMK, have shown promising anti-inflammatory effects in vitro and in pre-clinical PD models. The gene discussed is NLRP3; the disease is Parkinson disease.